aluates Reports

$ 0.0

Automative

Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Research Report 2024

Published Date: August 2024

Report Code: QYRE-Auto-3O18093

BUY CHAPTERS

Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Research Report 2024

Code: QYRE-Auto-3O18093

Report

August 2024

Pages:63

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Novo Nordisk

Eli Lilly

GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market

GLP-1 agonists are a class of pharmaceutical agents used to treat both type 2 diabetes mellitus and obesity,including semaglutide,liraglutide,tirzepatide,and others,which can stimulate GLP-1 receptors,leading to increased insulin secretion in response to meals,decreased glucagon release,and slowed gastric emptying.While GLP-1 agonists can also promote weight loss by enhancing feelings of fullness and decreasing appetite.

The global GLP-1 Agonists for the Treatment of both Diabetes and Obesity market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.

North American market for GLP-1 Agonists for the Treatment of both Diabetes and Obesity is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Asia-Pacific market for GLP-1 Agonists for the Treatment of both Diabetes and Obesity is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The global market for GLP-1 Agonists for the Treatment of both Diabetes and Obesity in Hospital and Clinic is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The major global companies of GLP-1 Agonists for the Treatment of both Diabetes and Obesity include Novo Nordisk, Eli Lilly, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for GLP-1 Agonists for the Treatment of both Diabetes and Obesity, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding GLP-1 Agonists for the Treatment of both Diabetes and Obesity.

The GLP-1 Agonists for the Treatment of both Diabetes and Obesity market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global GLP-1 Agonists for the Treatment of both Diabetes and Obesity market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the GLP-1 Agonists for the Treatment of both Diabetes and Obesity companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Report

Report Metric	Details
Report Name	GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market
Segment by Type	Semaglutide Liraglutide Tirzepatide
Segment by Application	Hospital and Clinic Retail Pharmacies Other
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Novo Nordisk, Eli Lilly
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of GLP-1 Agonists for the Treatment of both Diabetes and Obesity company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market report?

Ans: The main players in the GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market are Novo Nordisk, Eli Lilly

What are the Application segmentation covered in the GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market report?

Ans: The Applications covered in the GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market report are Hospital and Clinic, Retail Pharmacies, Other

What are the Type segmentation covered in the GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market report?

Ans: The Types covered in the GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market report are Semaglutide, Liraglutide, Tirzepatide

Recommended Reports

GLP-1 Drugs

Obesity Medicines

Diabetes Drugs

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth Rate by Type: 2019 VS 2023 VS 2030

1.2.2 Semaglutide

1.2.3 Liraglutide

1.2.4 Tirzepatide

1.3 Market by Application

1.3.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Growth by Application: 2019 VS 2023 VS 2030

1.3.2 Hospital and Clinic

1.3.3 Retail Pharmacies

1.3.4 Other

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Perspective (2019-2030)

2.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Growth Trends by Region

2.2.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Historic Market Size by Region (2019-2024)

2.2.3 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecasted Market Size by Region (2025-2030)

2.3 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Dynamics

2.3.1 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Industry Trends

2.3.2 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Drivers

2.3.3 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Challenges

2.3.4 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top GLP-1 Agonists for the Treatment of both Diabetes and Obesity Players by Revenue

3.1.1 Global Top GLP-1 Agonists for the Treatment of both Diabetes and Obesity Players by Revenue (2019-2024)

3.1.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Market Share by Players (2019-2024)

3.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue

3.4 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Concentration Ratio

3.4.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue in 2023

3.5 Global Key Players of GLP-1 Agonists for the Treatment of both Diabetes and Obesity Head office and Area Served

3.6 Global Key Players of GLP-1 Agonists for the Treatment of both Diabetes and Obesity, Product and Application

3.7 Global Key Players of GLP-1 Agonists for the Treatment of both Diabetes and Obesity, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Breakdown Data by Type

4.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Historic Market Size by Type (2019-2024)

4.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecasted Market Size by Type (2025-2030)

5 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Breakdown Data by Application

5.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Historic Market Size by Application (2019-2024)

5.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (2019-2030)

6.2 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Growth Rate by Country: 2019 VS 2023 VS 2030

6.3 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2019-2024)

6.4 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2025-2030)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (2019-2030)

7.2 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2019-2024)

7.4 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2025-2030)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (2019-2030)

8.2 Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Growth Rate by Country: 2019 VS 2023 VS 2030

8.3 Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Region (2019-2024)

8.4 Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Region (2025-2030)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (2019-2030)

9.2 Latin America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Latin America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2019-2024)

9.4 Latin America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2025-2030)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (2019-2030)

10.2 Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2019-2024)

10.4 Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2025-2030)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Novo Nordisk

11.1.1 Novo Nordisk Company Details

11.1.2 Novo Nordisk Business Overview

11.1.3 Novo Nordisk GLP-1 Agonists for the Treatment of both Diabetes and Obesity Introduction

11.1.4 Novo Nordisk Revenue in GLP-1 Agonists for the Treatment of both Diabetes and Obesity Business (2019-2024)

11.1.5 Novo Nordisk Recent Development

11.2 Eli Lilly

11.2.1 Eli Lilly Company Details

11.2.2 Eli Lilly Business Overview

11.2.3 Eli Lilly GLP-1 Agonists for the Treatment of both Diabetes and Obesity Introduction

11.2.4 Eli Lilly Revenue in GLP-1 Agonists for the Treatment of both Diabetes and Obesity Business (2019-2024)

11.2.5 Eli Lilly Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Novo Nordisk

Eli Lilly

List of Tables

Table 1. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

Table 2. Key Players of Semaglutide

Table 3. Key Players of Liraglutide

Table 4. Key Players of Tirzepatide

Table 5. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

Table 6. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 7. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Region (2019-2024) & (US$ Million)

Table 8. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Region (2019-2024)

Table 9. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 10. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Region (2025-2030)

Table 11. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Trends

Table 12. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Drivers

Table 13. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Challenges

Table 14. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Restraints

Table 15. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Players (2019-2024) & (US$ Million)

Table 16. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Players (2019-2024)

Table 17. Global Top GLP-1 Agonists for the Treatment of both Diabetes and Obesity Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in GLP-1 Agonists for the Treatment of both Diabetes and Obesity as of 2023)

Table 18. Ranking of Global Top GLP-1 Agonists for the Treatment of both Diabetes and Obesity Companies by Revenue (US$ Million) in 2023

Table 19. Global 5 Largest Players Market Share by GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue (CR5 and HHI) & (2019-2024)

Table 20. Global Key Players of GLP-1 Agonists for the Treatment of both Diabetes and Obesity, Headquarters and Area Served

Table 21. Global Key Players of GLP-1 Agonists for the Treatment of both Diabetes and Obesity, Product and Application

Table 22. Global Key Players of GLP-1 Agonists for the Treatment of both Diabetes and Obesity, Date of Enter into This Industry

Table 23. Mergers & Acquisitions, Expansion Plans

Table 24. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Type (2019-2024) & (US$ Million)

Table 25. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Market Share by Type (2019-2024)

Table 26. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 27. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Market Share by Type (2025-2030)

Table 28. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application (2019-2024) & (US$ Million)

Table 29. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Market Share by Application (2019-2024)

Table 30. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 31. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Market Share by Application (2025-2030)

Table 32. North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 33. North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2019-2024) & (US$ Million)

Table 34. North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2025-2030) & (US$ Million)

Table 35. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 36. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2019-2024) & (US$ Million)

Table 37. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2025-2030) & (US$ Million)

Table 38. Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 39. Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Region (2019-2024) & (US$ Million)

Table 40. Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Region (2025-2030) & (US$ Million)

Table 41. Latin America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 42. Latin America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2019-2024) & (US$ Million)

Table 43. Latin America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2025-2030) & (US$ Million)

Table 44. Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 45. Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2019-2024) & (US$ Million)

Table 46. Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2025-2030) & (US$ Million)

Table 47. Novo Nordisk Company Details

Table 48. Novo Nordisk Business Overview

Table 49. Novo Nordisk GLP-1 Agonists for the Treatment of both Diabetes and Obesity Product

Table 50. Novo Nordisk Revenue in GLP-1 Agonists for the Treatment of both Diabetes and Obesity Business (2019-2024) & (US$ Million)

Table 51. Novo Nordisk Recent Development

Table 52. Eli Lilly Company Details

Table 53. Eli Lilly Business Overview

Table 54. Eli Lilly GLP-1 Agonists for the Treatment of both Diabetes and Obesity Product

Table 55. Eli Lilly Revenue in GLP-1 Agonists for the Treatment of both Diabetes and Obesity Business (2019-2024) & (US$ Million)

Table 56. Eli Lilly Recent Development

Table 57. Research Programs/Design for This Report

Table 58. Key Data Information from Secondary Sources

Table 59. Key Data Information from Primary Sources

Table 60. Authors List of This Report

List of Figures

Figure 1. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Picture

Figure 2. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Comparison by Type (2024-2030) & (US$ Million)

Figure 3. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Type: 2023 VS 2030

Figure 4. Semaglutide Features

Figure 5. Liraglutide Features

Figure 6. Tirzepatide Features

Figure 7. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application (2024-2030) & (US$ Million)

Figure 8. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Application: 2023 VS 2030

Figure 9. Hospital and Clinic Case Studies

Figure 10. Retail Pharmacies Case Studies

Figure 11. Other Case Studies

Figure 12. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Report Years Considered

Figure 13. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 14. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 15. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Region: 2023 VS 2030

Figure 16. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Players in 2023

Figure 17. Global Top GLP-1 Agonists for the Treatment of both Diabetes and Obesity Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in GLP-1 Agonists for the Treatment of both Diabetes and Obesity as of 2023)

Figure 18. The Top 10 and 5 Players Market Share by GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue in 2023

Figure 19. North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 20. North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Country (2019-2030)

Figure 21. United States GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 22. Canada GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 23. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 24. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Country (2019-2030)

Figure 25. Germany GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 26. France GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 27. U.K. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 28. Italy GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. Russia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. Nordic Countries GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 31. Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 32. Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Region (2019-2030)

Figure 33. China GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 34. Japan GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 35. South Korea GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 36. Southeast Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 37. India GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 38. Australia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 39. Latin America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 40. Latin America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Country (2019-2030)

Figure 41. Mexico GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 42. Brazil GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 43. Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 44. Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Country (2019-2030)

Figure 45. Turkey GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 46. Saudi Arabia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 47. UAE GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 48. Novo Nordisk Revenue Growth Rate in GLP-1 Agonists for the Treatment of both Diabetes and Obesity Business (2019-2024)

Figure 49. Eli Lilly Revenue Growth Rate in GLP-1 Agonists for the Treatment of both Diabetes and Obesity Business (2019-2024)

Figure 50. Bottom-up and Top-down Approaches for This Report

Figure 51. Data Triangulation

Figure 52. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global GLP 1 Agonists for Obesity Market Research Report 2024

Global Glucagon Like Peptide 1 GLP 1 Agonists Market Research Report 2025

Global Antidiabetic Glucagon like Peptide 1 Agonists Market Research Report 2025

Global GLP 1 Agonist Injection Market Research Report 2024

GLP Analogs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Oral GLP 1 Agonist Market Research Report 2024

Global Liraglutide for The Treatment of Diabetes and Obesity Market Research Report 2024

Global GLP 1 Weight Loss Pill Market Research Report 2024

Global Glucagon like peptide 1 GLP 1 based Therapies Market Research Report 2025

Global GLP 1 Receptor Antagonist Market Research Report 2024

GLP 1 for Weight Loss Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global GLP 1RA based Therapy for Obesity Market Research Report 2024

Global GLP 1 Drugs Market Research Report 2024

Global GLP 1 Weight Loss Injection Market Research Report 2024

Global GLP 1 Weight Loss Drug Market Research Report 2024

Global Semaglutide Preparations Market Research Report 2024

Global Semaglutide Injection Market Research Report 2024

GLP 1 Analogues Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global GLP 1RA Therapy Market Research Report 2024

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions